Clinical trials: Relapsed and Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at…
- Trial name
- NCT05652335
- Testing
- JNJ-79635322
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Primary objective: To assess the safety of ITF 2357 administered once weekly at high pulse dose in patients with relapsing/refractory multiple myeloma. Secondary objectives: 1.
- Trial name
- NCT00792506
- Testing
- ITF2357
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Italfarmaco
Multiple Myeloma
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
The purpose of this study is to provide bortezomib to patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory or have relapse after their last treatment.
- Trial name
- NCT00440635
- Testing
- Bortezomib, tradename Velcade
- Volunteers
- 641 people
- Sponsor
- Janssen-Cilag International NV
Relapsed/Refractory Multiple Myeloma
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
This is an investigator-initiated, single-center, early-phase clinical study comprising dose escalation and dose expansion phases, designed to evaluate the safety and efficacy of IMV102 in subjects with relapsed/refractory…
- Trial name
- NCT07493135
- Testing
- IMV102 treatment
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Multiple Myeloma
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory…
- Trial name
- SCORE (NCT02628704)
- Testing
- Selinexor, carfilzomib, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines…
- Trial name
- NCT02852837
- Testing
- Daratumumab
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and…
- Trial name
- NCT02773030
- Testing
- CC-220, Dexamethasone, Daratumumab
- Where
- 162 sites in United States, Australia and 9 more
- Volunteers
- 466 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell.
- Trial name
- TRIlogy-3 (NCT07266441)
- Testing
- JNJ-79635322
- Where
- 71 sites in United States, China and 6 more
- Volunteers
- 168 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal…
- Trial name
- NCT04973605
- Testing
- Sonrotoclax, Dexamethasone, Carfilzomib
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 246 people
- Sponsor
- BeOne Medicines
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Relapsed or Refractory Multiple Myeloma (RRMM)
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Primary Purpose Phase Ib. To determine the Maximum Tolerated Dose (MTD) and establish the Recommended Phase IIa Dose (RP2D) of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in…
- Trial name
- NCT06484829
- Testing
- Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT01592370
- Testing
- Nivolumab, Ipilimumab, Lirilumab
- Where
- 43 sites in United States, Belgium and 4 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma(MM)
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple…
- Trial name
- NCT07100067
- Testing
- LCAR- F33S cells intravenous infusion
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
- Trial name
- COSTIMM (NCT06669247)
- Testing
- Linvoseltamab, REGN7945+Linvoseltamab
- Where
- 9 sites in Australia, United Kingdom
- Volunteers
- 186 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome…
- Trial name
- DARVIVA (NCT06296121)
- Testing
- BCD-264, Darzalex
- Where
- 14 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Biocad
Multiple Myeloma
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT05271682
- Testing
- FHND6091
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change)…
- Trial name
- MajesTEC-10 (NCT06425991)
- Testing
- Teclistamab
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with…
- Trial name
- NCT02477891
- Testing
- Daratumumab
- Where
- 79 sites in United States, Brazil and 4 more
- Sponsor
- Janssen Research & Development, LLC